Citations

Institution: Mayo Clinic Clear

Showing 10 of 108162 citations.

Survival outcome of metastatic pulmonary sarcomatoid carcinoma in immunotherapy era: An NCDB analysis.
Perimbeti, Stuthi, Chen, Hongbin , Liu, Bolun , Jiang, Changchuan , Attwood, Kristopher M. , Deng, Lei

Journal of Clinical Oncology | June 28, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 8555-8555

10.1200/jco.2024.42.16_suppl.8555 Get It

8555 Background: Pulmonary sarcomatoid carcinoma (PSC) is a rare subtype of non-small cell lung cancer (NSCLC), with historically poor outcome. Excellent response of metastatic PSC to immunotherapy was previously reported, but its outcome compared with other NSCLCs is unknown in the immunotherapy era. Methods: NCDB was queried for stage IV NSCLC diagnosed from 2016 to 2020. Patients who were treated with chemotherapy only or immunotherapy only in the first course of treatment were included. Log-rank was used for survival analysis and adjusted by cox regression for age, gender, race, academic/integrated center, insurance, and comorbidity. Results: A total of 37,617 patients were identified, including 201 PSCs and 37,416 other NSCLCs. Pleomorphic (54%) was the most common PSC subtype. There was significant interaction between the survival effect of treatment and histology (interaction p = 0.024). When treated with immunotherapy alone, no significant difference was found between PSC and other NSCLCs (median survival 11.4 vs 12.4 months, logrank p = 0.56, HR 1.02, 95% CI 0.81 – 1.30). However, when treated with chemotherapy alone, PSC remained significantly associated with worse survival (median survival 4.5 vs. 8.5 months, logrank p <0.001, HR 0.67, 95% CI 0.54 – 0.83). Among PSC subtypes, spindle/giant cell PSCs were more likely to benefit from immunotherapy alone than pleomorphic PSCs (interaction p = 0.005), when compared with chemotherapy (Spindle/giant cell subtype: HR 0.24, 95% CI 0.14 – 0.42; Pleomorphic subtype: HR 0.60, 95% CI 0.37 – 0.99). Conclusions: Compared with other NSCLCs, PSC may not be associated with worse survival when treated with immunotherapy alone as it was when treated with chemotherapy. Distinct PSC subtypes may respond differently to immunotherapy and warrants further research. [Table: see text]
Clinical and imaging presentations are associated with function in incidental adrenocortical adenomas: a retrospective cohort study
Hamidi, Oksana , Shah, Muhammad Shahmeer Ullah , Zhang, Catherine D , Lazik, Natalia, Li, Dingfeng , Singh, Sumitabh , Iñiguez‐Ariza, Nicole M. , Raman, Ram, Carafone, Lindsay , Khanna, Aakanksha, Yan, Qi , Natt, Neena, Hartman, Robert P. , McKenzie, Travis J. , Yan, Qi , Bancos, Irina , Hamidi, Oksana , Shah, Muhammad, Hurtado, Maria D. , Young, William F. , Bancos, Irina

European Journal of Endocrinology | June 28, 2024 | Volume: 191 | Issue: 1 | Pages: 47-54

10.1093/ejendo/lvae078 | PMID 38941271 Get It

Abstract Objective The aim of this study is to assess whether clinical and imaging characteristics are associated with the hormonal subtype, growth, and adrenalectomy for incidental adrenal cortical adenomas (ACAs). Design This is a single-center cohort study. Methods Consecutive adult patients with incidental ACA were diagnosed between 2000 and 2016. Results Of the 1516 patients with incidental ACA (median age 59 years, 62% women), 699 (46%) had nonfunctioning adenomas (NFAs), 482 (31%) had mild autonomous cortisol secretion (MACS), 62 (4%) had primary aldosteronism (PA), 39 (3%) had Cushing syndrome, 18 (1%) had PA and MACS, and 226 (15%) had incomplete work-up. Age, sex, tumor size, and tumor laterality, but not unenhanced computed tomography Hounsfield units (HU), were associated with hormonal subtypes. In a multivariable analysis, ≥1 cm growth was associated with younger age (odds ratio [OR] = 0.8 per 5-year increase, P = .0047) and longer imaging follow-up (OR = 1.2 per year, P &lt; .0001). Adrenalectomy was performed in 355 (23%) patients, including 38% of MACS and 15% of NFA. Adrenalectomy for NFA and MACS was more common in younger patients (OR = 0.79 per 5-year increase, P = .002), larger initial tumor size (OR = 2.3 per 1 cm increase, P &lt; .0001), ≥1 cm growth (OR = 15.3, P &lt; .0001), and higher postdexamethasone cortisol (OR = 6.6 for &gt;5 vs &lt;1.8 μg/dL, P = .002). Conclusions Age, sex, tumor size, and laterality were associated with ACA hormonal subtype and can guide diagnosis and management. Tumor growth was more common with younger age and longer follow-up. Unenhanced HU did not predict hormonal subtype or growth. Adrenalectomy for MACS and NFA was mainly performed in younger patients with larger tumor size, growth, and elevated postdexamethasone cortisol.
Echocardiogram Vector Embeddings Via R3D Transformer for the Improvement of Ejection Fraction Estimation Instruments
Lee, Somin Mindy , Chung, Daniel, Kaker, Vasu, Zhao, Yongyi, Perera, Sudheesha , Sasankan, Prabhu, Tang, George, Kpodonu, Jacques , Kazzi, Brigitte , Chung, Daniel J, Riaz, Irbaz Bin , Tang, George, Kuo, Po‐Chih , Celi, Leo Anthony

2024 IEEE International Instrumentation and Measurement Technology Conference (I2MTC) | June 28, 2024 | Volume: No volume available | Issue: No issue available | Pages: 1-6

10.1109/i2mtc60896.2024.10561175 Get It

Lisocabtagene maraleucel (liso-cel) vs standard of care (SOC) with salvage chemotherapy (CT) followed by autologous stem cell transplantation (ASCT) as second-line (2L) treatment in patients (pt) with R/R large B-cell lymphoma (LBCL): 3-year follow-up (FU)
Solomon, Scott R. , Arnason, Jon , Johnston, Patrick B. , Glaß, Bertram , Mutsaers, Pim , Hernandez‐Ilizaliturri, Francisco J. , Lunning, Matthew A. , Chow, Victor A. , Santamaria, Josu, Colicino, Silvia , Stepan, Lara , Kamdar, Manali , Bachanová, Veronika , Ibrahimi, Sami , Mielke, Stephan , Izutsu, Koji , Morschhauser, Franck , Ogasawara, Ken , Abramson, Jeremy S.

Journal of Clinical Oncology | June 28, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 7013-7013

10.1200/jco.2024.42.16_suppl.7013 Get It

7013 Background: Liso-cel is an autologous, CD19-directed, 4-1BB CAR T cell product. In prespecified interim and primary analyses of TRANSFORM (NCT03575351), liso-cel showed significant improvements in efficacy vs SOC in pts with R/R LBCL. Here we report results after ~3-y FU. Methods: TRANSFORM is a randomized phase 3 study comparing liso-cel vs SOC (CT [R-DHAP, R-ICE, or R-GDP] then high-dose CT [HDCT] + ASCT) in adults aged ≤ 75 y with LBCL primary refractory to or relapsed ≤ 12 mo after first-line therapy and eligible for ASCT. Liso-cel arm pts underwent lymphodepletion followed by liso-cel (100 × 10 6 CAR + T cells). Bridging therapy was allowed. SOC arm pts received 3 cycles of CT; responding pts proceeded to HDCT + ASCT. Crossover to receive liso-cel was allowed for SOC arm pts if criteria were met. The primary endpoint was event-free survival (EFS) per independent review committee (IRC). Key secondary endpoints included CR rate and PFS per IRC, and OS. Endpoints were not statistically retested and are reported descriptively. Results: In total, 184 pts were randomized (92 per arm); baseline characteristics were reported (Abramson et al. Blood 2023). Median (range) FU was 33.9 mo (0.9–53.0). Median EFS, PFS, and duration of response (DOR) were longer for liso-cel vs SOC, similar to the primary analysis (Table). A total of 61 (66%) SOC arm pts crossed over to receive liso-cel. Median OS was not reached (NR) in either arm; 36-mo OS rates were numerically higher for liso-cel. Of 76 total deaths (liso-cel, n = 34; SOC, n = 42 [crossover pts, n = 33]), 10 occurred since the primary analysis (liso-cel, n = 6; SOC, n = 4 [all crossover pts]); most were due to disease progression or complications (n = 6). Safety results were consistent with the primary analysis. Cellular kinetics and B-cell aplasia will be presented. Conclusions: After median FU of 33.9 mo, liso-cel as 2L treatment in pts with primary refractory or early relapsed LBCL resulted in deepening of response and continued improvement in efficacy endpoints over SOC, confirming the ongoing benefit of liso-cel. Clinical trial information: NCT03575351 . [Table: see text]
Contemporary Issue: Health and Safety of Female Wrestlers
Moschelli, Jill S., Woodroffe, Lisa , Horswill, Craig A. , Bloomfield, Susan A. , Oppliger, Robert A., Jagim, Andrew R.

Current Sports Medicine Reports | June 28, 2024 | Volume: 23 | Issue: 7 | Pages: 262-269

10.1249/jsr.0000000000001183 | PMID 38941548 Get It

Abstract Female wrestling has grown exponentially over the past decade. Within the United States, 46 states now recognize female high school wrestling, and 153 colleges have programs. It is on track to become an NCAA championship-level sport in 2026. A primary health and safety risk among this cohort pertains to rapid weight loss strategies. These can lead to intentional caloric restriction and decreased body fatness, with the perceived goal of attaining a competitive advantage. Low energy availability and low body fatness are associated with a number of health concerns including menstrual dysfunction and loss of bone mineral density in girls and women. The current recommendation of 12% as a minimum for percentage body fat is very likely too low, opening the door for health perturbations among this population. The minimum threshold might more appropriately fall within the range of 18% to 20%. Body fat assessment methods, primarily skinfold measures that are used to guide weight class selection, have not been adequately validated among this population and therefore should be an area of research focus, while also exploring alternative assessment techniques. Further, we recommend that weight cycling, restrictive energy intake, and intentional dehydration be avoided. Research should assess the effects of frequent weight cycling (to “make weight”) and prolonged periods of low body fat on the reproductive and bone health of these athletes. Finally, research and clinical evaluations on female wrestlers are limited, and we offer a list of research priorities for future investigation into this contemporary issue.
Prognostic role of suPAR in acute pancreatitis: A protocol for systematic review
Rehan, Syeda Tayyaba , Imran, Laiba , Eqbal, Farea , Khan, Zayeema , Nashwan, Abdulqadir J. , Asghar, Muhammad Sohaib , Asghar, Muhammad S

Medicine | June 28, 2024 | Volume: 103 | Issue: 26 | Pages: e37064

10.1097/md.0000000000037064 | PMID 38941433 Get It

Background: Acute pancreatitis (AP) is a common emergency condition with high morbidity, mortality, and socio-economic impact. Soluble urokinase plasminogen activator receptor (suPAR) is a potential biomarker for AP prognosis. This study systematically reviews the literature on suPAR’s prognostic roles in assessing AP severity, organ failure, mortality, and other pathological markers. Methods: A comprehensive search of 5 databases up to March 19, 2023, was conducted, selecting cohort studies that examined suPAR’s relationship with AP outcomes. Outcome variables included AP severity, organ failure, mortality, hospital stay length, and suPAR’s association with other inflammatory markers. Our paper has been registered on Prospero (ID: CRD42023410628). Results: Nine prospective observational studies with 1033 AP patients were included. Seven of eight studies found suPAR significantly elevated in severe acute pancreatitis ( P < .05). Four studies showed suPAR effectively predicted organ failure risk, and 4 studies concluded suPAR significantly predicted mortality ( P < .05). The review had no high-risk studies, enhancing credibility. Conclusion: suPAR is a valuable prognostic marker in AP, significantly predicting severity, organ failure, hospital stay length, and mortality. Further large-scale studies are needed to explore suPAR’s role in other clinical outcomes related to AP disease course, to establish it as a mainstay of AP prognosis.
The MAGIC algorithm probability predicts treatment response and long-term outcomes to second-line therapy for acute GVHD
DeFilipp, Zachariah , Spyrou, Nikolaos , Katsivelos, Nikolaos , Kowalyk, Steven, Eng, Gilbert, Kasikis, Stelios, Beheshti, Rahnuma, Baez, Janna , Akahoshi, Yu , Ayuk, Francis, Choe, Hannah , Etra, Aaron , Vášová, Ingrid, Young, Rachel , Holler, Ernst , Ferrara, James L.M. , Nakamura, Ryotaro , Chen, Yi‐Bin , Katsivelos, Nikolaos , Akahoshi, Yu , Hexner, Elizabeth , Hogan, William J , Qayed, Muna , Reshef, Ran , Nakamura, Ryotaro , Levine, John E , Chen, Yi-Bin , Kim, Haesook T. , Grupp, Stephan A. , Hexner, Elizabeth O. , Hogan, William J. , Kitko, Carrie L. , Reshef, Ran , Zeiser, Robert , Levine, John E.

Blood Advances | June 28, 2024 | Volume: 8 | Issue: 13 | Pages: 3488-3496

10.1182/bloodadvances.2024012561 | PMID 38640197 Get It

Abstract The significance of biomarkers in second-line treatment for acute graft-versus-host disease (GVHD) has not been well characterized. We analyzed clinical data and serum samples at the initiation of second-line systemic treatment of acute GVHD from 167 patients from 17 centers of the Mount Sinai Acute GVHD International Consortium (MAGIC) between 2016 and 2021. Sixty-two patients received ruxolitinib-based therapy, whereas 102 received other systemic agents. In agreement with prospective trials, ruxolitinib resulted in a higher day 28 (D28) overall response Frate than nonruxolitinib therapies (55% vs 31%, P = .003) and patients who received ruxolitinib had significantly lower nonrelapse mortality (NRM) than those who received nonruxolitinib therapies (point estimates at 2-year: 35% vs 61%, P = .002). Biomarker analyses demonstrated that the benefit from ruxolitinib was observed only in patients with low MAGIC algorithm probabilities (MAPs) at the start of second-line treatment. Among patients with a low MAP, those who received ruxolitinib experienced significantly lower NRM than those who received nonruxolitinib therapies (point estimates at 2-year: 12% vs 41%, P = .016). However, patients with high MAP experienced high NRM regardless of treatment with ruxolitinib or nonruxolitinib therapies (point estimates at 2-year: 67% vs 80%, P = .65). A landmark analysis demonstrated that the relationship between the D28 response and NRM largely depends on the MAP level at the initiation of second-line therapy. In conclusion, MAP measured at second-line systemic treatment for acute GVHD predicts treatment response and NRM. The outcomes of patients with high MAP are poor regardless of treatment choice, and ruxolitinib appears to primarily benefit patients with low MAP.
Glycolysis in hepatic stellate cells coordinates fibrogenic extracellular vesicle release spatially to amplify liver fibrosis
Khanal, Shalil , Liu, Yuanhang , Wixom, Alexander Q. , Washington, Alexander M. , Jalan‐Sakrikar, Nidhi , Cooper, Shawna A. , Vučković, Ivan , Zhang, Song , Zhong, Jun , Johnson, Kenneth L. , Charlesworth, M. Cristine , Kim, I.Y. , Yeon, Yubin, Yoon, Sangwoong , Noh, Yung‐Kyun , Meroueh, Chady , Timbilla, Abdul Aziz , Yaqoob, Usman , Gao, Jinhang , Kim, Yohan , Hay, Nissim , Shah, Vijay H. , Bamidele, Adebowale O , Wixom, Alexander Q , Washington, Alexander M , Sakrikar, Nidhi Jalan , Cooper, Shawna A , Vuckovic, Ivan , Zhang, Song , Zhong, Jun , Johnson, Kenneth , Kim, Iljung , Yeon, Yubin , Yoon, Sangwoong , Noh, Yung-Kyun , Meroueh, Chady , Timbilla, Abdul Aziz , Gao, Jinhang , Kim, Yo Han , Lucien, Fabrice , Simons, Michael , Shah, Vijay H , Kostallari, Enis , Liu, Yuanhang, Bamidele, Adebowale O. , Charlesworth, M. Cristine , Yaqoob, Usman , Lucien, Fabrice , Huebert, Robert C. , Simons, Michael , Kostallari, Enis

Science Advances | June 28, 2024 | Volume: 10 | Issue: 26 | Pages: No page available

10.1126/sciadv.adn5228 | PMID 38941469 Get It

Liver fibrosis is characterized by the activation of perivascular hepatic stellate cells (HSCs), the release of fibrogenic nanosized extracellular vesicles (EVs), and increased HSC glycolysis. Nevertheless, how glycolysis in HSCs coordinates fibrosis amplification through tissue zone-specific pathways remains elusive. Here, we demonstrate that HSC-specific genetic inhibition of glycolysis reduced liver fibrosis. Moreover, spatial transcriptomics revealed a fibrosis-mediated up-regulation of EV-related pathways in the liver pericentral zone, which was abrogated by glycolysis genetic inhibition. Mechanistically, glycolysis in HSCs up-regulated the expression of EV-related genes such as Ras-related protein Rab-31 ( RAB31 ) by enhancing histone 3 lysine 9 acetylation on the promoter region, which increased EV release. Functionally, these glycolysis-dependent EVs increased fibrotic gene expression in recipient HSC. Furthermore, EVs derived from glycolysis-deficient mice abrogated liver fibrosis amplification in contrast to glycolysis-competent mouse EVs. In summary, glycolysis in HSCs amplifies liver fibrosis by promoting fibrogenic EV release in the hepatic pericentral zone, which represents a potential therapeutic target.
Pharyngolaryngeal Venous Plexus Mimicking Recurrent Hypopharyngeal Cancer
Brahmbhatt, Sneh , Bhatt, Alok A. , Bhatt, Alok A

Radiology: Imaging Cancer | June 28, 2024 | Volume: 6 | Issue: 4 | Pages: No page available

10.1148/rycan.240039 | PMID 38940691 Get It

Medical, Psychiatric, and Sociodemographic Predictors of Clozapine Initiation at an Academic Medical Center
Shangraw, Kathleen , Schmutz, Christian , Dowdle, Tom, Kelley, Ryan, Porter, C B, Reynolds, Merrick, Schwartz, Zachary , Sutton, Olivia, Kious, Brent M. , Porter, Caleb, Kelley, Ryan

Psychiatric Research and Clinical Practice | June 28, 2024 | Volume: 6 | Issue: 3 | Pages: 104-111

10.1176/appi.prcp.20240056 | PMID 39568504 Get It

Background and Hypothesis Clozapine is an effective yet underutilized treatment for treatment‐resistant schizophrenia spectrum disorders. This study aimed to identify factors affecting clozapine prescribing patterns among patients with treatment‐resistant schizophrenia and schizoaffective disorder at an academic medical center. Study Design This retrospective combined cohort and case‐control study examined demographic, socioeconomic, medical and psychiatric characteristics to determine predictors of clozapine initiation. Eligible patients had a diagnosis of schizophrenia or schizoaffective disorder with at least two prior antipsychotic trials and were admitted to a University of Utah inpatient psychiatric facility (1/2014–3/2021). Patients who did and did not receive clozapine during the index hospitalization were compared in cohort and case‐control study arms. Study Results Twelve percent (59/477) of the cohort received clozapine during the index admission. Among the cohort ( n = 477), Black patients were twice as likely to receive clozapine than White and Hispanic patients (OR 2.18, 95% CI 1.20–3.97, p = 0.008). In the case‐control analysis, patients with a greater number of previous psychiatric admissions (OR 1.14, p = 0.079) and antipsychotic trials (OR 1.40, p = 0.038) had greater odds of receiving clozapine. Homelessness was identified as a predictor against clozapine use (OR 2.77, p = 0.014). Conclusions This is the first study to identify homelessness as a predictor against clozapine use, which raises important clinical and ethical considerations. Our findings also add to the literature on clozapine prescribing discrepancies among ethnic‐minority patients. Overall, clozapine remains underutilized as the gold‐standard treatment for treatment‐resistant schizophrenia‐spectrum disorders, reinforcing a need to improve evidence‐based prescribing.